EUVIMEDEUVIMED entdecken
Crossref

Laboratory Monitoring in Patients Receiving Emicizumab

Jens Müller, Martin Büchsel, Olga Oleshko, Behnaz Pezeshkpoor iD, Ulrich Sachs, Ute Scholz, Andreas Tiede

Hämostaseologie · 09.10.2025

DOI: 10.1055/a-2687-0107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hämostaseologie, online erschienen am 09.10.2025. Verfasst von Jens Müller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 87 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emicizumab is a bispecific monoclonal antibody that mimics the cofactor function of activated factor VIII (FVIIIa). It is approved for routine prophylaxis in patients with severe or moderate congenital hemophilia A (HA), both with and without FVIII inhibitors, and is increasingly used as a first-line treatment in acquired HA (AHA). Owing to its predictable pharmacokinetic profile, emicizumab monitoring is generally limited to cases with suspected reduced efficacy, such as due to poor adherence or the development of anti-drug antibodies (ADAs). However, emicizumab interferes with standard clotting assays, particularly by shortening activated partial thromboplastin times (APTT). To address this, modified FVIII one-stage clotting assays (mOSA), which use higher sample pre-dilution and emicizumab-specific calibration, are commonly employed to estimate plasma levels, although other assay formats like emicizumab-calibrated chromogenic substrate assays based on human factors or liquid chromatography tandem mass spectrometry are also available. Additionally, global assays such as in vitro thrombin generation testing are being explored to better reflect clinical hemostatic efficacy. This review summarizes current knowledge on assay interferences caused by emicizumab, challenges in functional measurement of plasma levels, and strategies to ensure reliable laboratory assessment. We also discuss the relevance and methods for ADA detection and provide an overview of current and emerging strategies for thrombin generation measurement as a global indicator of treatment effectiveness.

Autor:innen und Institutionen

  • Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
  • Institute for Clinical Chemistry and Laboratory Medicine, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany.
  • Center of Coagulation Disorders, Leipzig, Germany.

ORCID-Profile: Behnaz Pezeshkpoor

Zitieren

APA

Müller, J., Büchsel, M., Oleshko, O., Pezeshkpoor, B., Sachs, U., Scholz, U., & Tiede, A. (2025). Laboratory Monitoring in Patients Receiving Emicizumab. Hämostaseologie. https://doi.org/10.1055/a-2687-0107

Vancouver

Müller J, Büchsel M, Oleshko O, Pezeshkpoor B, Sachs U, Scholz U, et al. Laboratory Monitoring in Patients Receiving Emicizumab. Hämostaseologie. 2025. doi:10.1055/a-2687-0107

BibTeX
@article{Mller2025,
  author = {Müller, Jens and Büchsel, Martin and Oleshko, Olga and Pezeshkpoor, Behnaz and Sachs, Ulrich and Scholz, Ute and Tiede, Andreas},
  title = {Laboratory Monitoring in Patients Receiving Emicizumab},
  journal = {Hämostaseologie},
  year = {2025},
  doi = {10.1055/a-2687-0107}
}
Kostenlos starten →